⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 23, 2024The Lancet Infectious DiseasesOpen Access

Effectiveness of rVSV-ZEBOV vaccination during the 2018–20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study

Sophie Meakin Justus Nsio Anton Camacho Richard Kitenge Rebecca M. Coulborn Etienne Gignoux John Johnson Esther Sterk Elisabeth Mukamba Musenga Stéphane Hans Bateyi Mustafa Flavio Finger Steve Ahuka‐Mundeke

View Full Paper

Ask AI

Bookmark

Share

Abstract

The recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) vaccine is the only WHO prequalified vaccine recommended for use to respond to outbreaks of Ebola virus (species Zaire ebolavirus) by WHO's Strategic Advisory Group of Experts on Immunization. Despite the vaccine's widespread use during several outbreaks, no real-world effectiveness estimates are currently available in the literature.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Meakin et al. (2024) studied this question.

synapsesocial.com/papers/68e5b146b6db64358754aedc https://doi.org/10.1016/s1473-3099(24)00419-5

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Use of Ebola Vaccines — Worldwide, 2021–20232024 · 29 citations
2rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai Proches)2024
3Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the CongoCohort Study · 2022 · 19 citations
4EBOLA VIRUS VACCINES AND RECENT ADVANCEMENTS: A SCOPING REVIEWReview · 2026
5EBOLA VIRUS VACCINES AND RECENT ADVANCEMENTS: A SCOPING REVIEWReview · 2026

More related papers

Knowledge, attitudes, and practices and long-term immune response after rVSVΔG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in Uganda2024
P-1432. Communicating Readiness: Lessons Learned and Key Takeaways from an Ebola Vaccine Rollout at a Regional Emerging Special Pathogens Treatment Center2026
Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases2024

More from The Lancet Infectious Diseases

African countries' effort to interrupt polio outbreaksWed,
Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, evaluated with and without tetanus-reduced diphtheria-acellular pertussis vaccine in healthy children aged 6–17 years: a randomised, active-controlled and placebo-controlled, phase 2b trialThu,